Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 15;7(2):742-50.
eCollection 2014.

Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer

Chengzhi He  1 , Hua Jiang  2 , Shasha Geng  2 , Haihui Sheng  3 , Xiaoying Shen  3 , Xiaoyan Zhang  3 , Shizhang Zhu  3 , Ximei Chen  4 , Changqing Yang  4 , Hengjun Gao  5
Affiliations

Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer

Chengzhi He et al. Int J Clin Exp Pathol. .

Abstract

The identification of molecular prognostic markers for pancreatic cancer patients could provide insightful information for their management in the clinic. The aim of the study is to investigate whether or not the expressions of c-Myc and Fas (CD95/APO1) have prognostic relevance for overall survival (OS) in patients with pancreatic cancer. we used immunohistochemistry on tissue microarrays containing 162 pancreatic cancer specimens to assess the protein expression levels of c-Myc and Fas. Kaplan-Meier survival analysis demonstrated that high level of c-Myc cytoplasmic expression was significantly correlated with worse survival in patients with pancreatic cancer (P = 0.012), while high level of Fas cytoplasmic expression was significantly associated with better outcome of pancreatic cancer (P = 0.046). However, multivariate Cox model analysis showed that tumor differentiation, lymph node status and c-Myc cytoplasmic expression were significant independent prognostic factors for OS (P < 0.001, P = 0.023, P = 0.001, respectively). On the contrary, Fas cytoplasmic expression did not independently influence patient's prognosis (P = 0.249). Our data suggested that high level of c-Myc cytoplasmic expression may be considered as a valuable marker for prognosis of pancreatic cancer.

Keywords: Fas (CD95/APO1); Pancreatic cancer; c-Myc; immunohistochemistry; survival analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunohistochemical staining of c-Myc and Fas in human pancreatic cancer tissues and paracancerous tissues. A: Showing the positive expression of c-Myc in cancer tissues. B: Showing the negative expression of Fas in cancer tissues. C: Showing the negative expression of c-Myc in paracancerous tissues. D: Showing the positive expression of Fas in paracancerous tissues. All images were taken at 100× magnification.
Figure 2
Figure 2
Kaplan-Meier curves show that high cytoplasmic expression level of c-Myc (A) was significantly correlated with worse survival of patients with pancreatic cancer, while high cytoplasmic expression level of Fas (B) was significantly associated with better survival (n = 70; P = 0.012, P = 0.046, respectively; log rank test).
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu JQ, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ. 2012;344:e2476. - PubMed
    1. Gong ZH, Holly EA, Bracci PM. Survival in Population-based Pancreatic Cancer Patients: San Francisco Bay Area, 1995-1999. Am J Epidemiol. 2011;174:1373–1381. - PMC - PubMed
    1. Mitchem JB, Hamilton N, Gao F, Hawkins WG, Linehan DC, Strasberg SM. Long-Term Results of Resection of Adenocarcinoma of the Body and Tail of the Pancreas Using Radical Antegrade Modular Pancreatosplenectomy Procedure. J Am Coll Surg. 2012;214:46–52. - PubMed
    1. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PWT, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 2008;26:3496–3502. - PubMed

Publication types